ClinicalTrials.gg
Active, not recruitingNCT05952557CAMBRIA-2Updated Aug 10, 2026

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

A Phase 3 interventional study of Camizestrant and Tamoxifen in Breast Cancer, Early Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 661 sites in 44 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,511
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing AZD9833 in Breast Neoplasms — 6 open to participants now, 10 under way, 7 of them phase 3. AZD9833 · Breast Neoplasms.

Enrollment
Largest of 17
5,511 · median 150
Started
2023
with 1 other
Phase 3
7 of 17
4 open now
Registered
11th of 17
by date
Lead sponsor
15 of 17
AstraZeneca

Among the 17 studies testing AZD9833 in Breast Neoplasms, this one has the largest enrollment, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 11th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 17 studies testing AZD9833 in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About AZD9833

AZD9833: first FDA approval 2026 (ETCAMAH), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing AZD9833 in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Read the detailed description

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm of the study is 7 years. Eligible patients must have intermediate-high or high risk of recurrence as defined by specified clinical and biologic criteria. Concurrent use of abemaciclib is permitted in both arms. The primary endpoint of the study is Invasive breast cancer-free survival (IBCFS) and main secondary endpoints include Invasive disease-free survival (IDFS), Distant relapse-free survival (DRFS), Overall survival (OS), Safety and Clinical Outcome Assessments (COAs).

Patients will be followed for 10 years from randomization of the last patient.

03

Conditions studied

  • Breast Cancer, Early Breast Cancer

Browse trials for

Keywords

  • ER+
  • HER2-
  • breast cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women and Men; ≥18 years at the time of screening (or per national guidelines)
  • confirmed ER+/- early-stage resected invasive breast cancer with absence of any evidence of disease as defined in the protocol.
  • Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo) chemotherapy.
  • Patients must be randomised within 12 months of definitive breast surgery.
  • Patients may have received up to 12 weeks of endocrine therapy prior to randomisation.
  • (ECOG) performance status of ≤ 1
  • Adequate organ and bone marrow function

Exclusion criteria

Exclusion Criteria:

  • Inoperable locally advanced or breast cancer
  • Pathological complete response following treatment with therapy
  • History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered a very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation
  • Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion precludes participation in the study or compliance "
  • Known \<50% with heart failure Grade ≥2.
  • Mean resting interval > 480 ms at screening
  • Concurrent exogenous reproductive hormone therapy or non topical hormonal therapy for non-cancer-related conditions
  • Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors ( eg, denosumab)
  • Previous treatment with camizestrant, SERDs/investigational ER targeting agents, or fulvestrant
  • Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding.
  • Patients with known to active or inactive of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-/peri-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists that would preclude the patient from receiving any LHRH agonist.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,511 participants (actual)

Study arms

  • Active comparator
    Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib

    standard endocrine therapy of investigator's choice (aromatase inhibitors \[AI; exemestane, letrozole, anastrozole\] or tamoxifen) ± abemaciclib

    Drug: Tamoxifen · Drug: Anastrozole · Drug: Letrozole · Drug: Exemestane · Drug: Abemaciclib

  • Experimental
    Arm B: camizestrant ± abemaciclib

    camizestrant ± abemaciclib

    Drug: Camizestrant · Drug: Abemaciclib

Interventions

  • Camizestrant. Experimental. Administered orally

    Also known as: AZD9833

  • Tamoxifen. Comparator. Administered orally

  • Anastrozole. Comparator. Administered orally

  • Letrozole. Comparator. Administered orally

  • Exemestane. Comparator. Administered orally

  • Abemaciclib adjuvant treatment Administered orally

06

What researchers measure

Primary outcomes

  1. Invasive breast cancer-free survival (IBCFS)

    IBCFS is defined as time from randomisation until date of first occurrence of: * Invasive ipsilateral breast tumour recurrence * Locoregional invasive breast cancer recurrence * Distant recurrence * Contralateral invasive breast cancer * Death attributable to any cause.

    Time frame: Up to 14 years

Secondary outcomes

  1. Invasive disease-free survival (IDFS)

    IDFS is defined as time from randomisation until date of first occurrence of one of the following events: * Invasive ipsilateral breast tumor recurrence * Locoregional invasive breast cancer recurrence * Distant recurrence * Contralateral invasive breast cancer * Second primary non-breast invasive cancer * Death attributable to any cause.

    Time frame: Up to 14 years

  2. Distant relapse-free survival (DRFS)

    DRFS is defined as time from randomisation until date of first distant recurrence or death from any cause, whichever occurs first.

    Time frame: Up to 14 years

  3. Overall survival (OS)

    OS is defined as time from randomisation until death from any cause.

    Time frame: Up to 14 years

  4. Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0)

    Time frame: Until 28 days after the final dose of study treatment (up to 7 years)

  5. Proportion of time on study treatment with high side-effect burden as measured by the PGI-TT.

    Time frame: Until 28 days after the final dose of study treatment (up to 7 years)

  6. Change from baseline and time to deterioration of health-related quality of life as measured by the 2 global QoL items from the EORTC IL-311

    Time frame: Until 28 days after the final dose of study treatment (up to 7 years)

  7. Pharmacokinetics (PK)

    Plasma concentrations of camizestrant pre-dose (trough concentration)

    Time frame: Until 6 months from treatment start

07

Study locations

661 sites
  • Research Site
    Dothan, Alabama 36303, United States
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Tucson, Arizona 85745, United States
  • Research Site
    Fayetteville, Arkansas 72703, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Irvine, California 92618, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    West Hollywood, California 90048, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Littleton, Colorado 80120, United States
  • Research Site
    Littleton, Colorado 80129, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Gainesville, Florida 32610, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Pembroke Pines, Florida 33028, United States
  • Research Site
    Plantation, Florida 33322, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    St. Petersburg, Florida 33709, United States
  • Research Site
    Tallahassee, Florida 32308, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Thomasville, Georgia 31792, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Elmhurst, Illinois 60126, United States
  • Research Site
    Naperville, Illinois 60540, United States
  • Research Site
    Urbana, Illinois 61801, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Des Moines, Iowa 50309, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    New Orleans, Louisiana 70121, United States
  • Research Site
    Scarborough, Maine 04074, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Boston, Massachusetts 02111, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Ypsilanti, Michigan 48197, United States
  • Research Site
    Minneapolis, Minnesota 55416, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    St Louis, Missouri 63131, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Omaha, Nebraska 68124, United States
  • Research Site
    Hooksett, New Hampshire 03106, United States
  • Research Site
    Manchester, New Hampshire 03103, United States
  • Research Site
    New Brunswick, New Jersey 08901, United States
  • Research Site
    Albuquerque, New Mexico 87109, United States
  • Research Site
    Farmington, New Mexico 87401, United States
  • Research Site
    Bay Shore, New York 11706, United States
  • Research Site
    East Syracuse, New York 13057, United States
  • Research Site
    Greenlawn, New York 11740, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Stony Brook, New York 11794, United States
  • Research Site
    White Plains, New York 10601, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Pinehurst, North Carolina 28374, United States
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cincinnati, Ohio 45255, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Columbus, Ohio 43212, United States
  • Research Site
    Portland, Oregon 97210, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Portland, Oregon 97225, United States
  • Research Site
    Gettysburg, Pennsylvania 17325, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Sayre, Pennsylvania 18840, United States
  • Research Site
    York, Pennsylvania 17403, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Rock Hill, South Carolina 29732, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Aberdeen, South Dakota 57401, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Knoxville, Tennessee 37909, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Austin, Texas 78731, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Flower Mound, Texas 75028, United States
  • Research Site
    Houston, Texas 77024, United States
  • Research Site
    San Antonio, Texas 78217, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    Charlottesville, Virginia 22908, United States

Showing the first 100 of 661 sites across 44 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Hamilton EP, Loibl S, Bachelot T, Gnant M, Niikura N, Park YH, Tolaney SM, Pistilli B, Rastogi P, Saini KS, Gioni I, Johnston S, Nunes R, Quintana A, Stuart M, Syta E, Walding A, Klinowska T, Mayer IA. CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer. Future Oncol. 2025 Mar;21(7):795-806. doi: 10.1080/14796694.2025.2459548. Epub 2025 Feb 27. PubMed 40017004 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Mar 2030, 76 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 76 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
Jul 19, 2023
StartActual
Oct 5, 2023
Primary completionEst.
Mar 4, 2030
CompletionEst.
May 6, 2037
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05952557
Lead sponsor
AstraZeneca
Collaborators
Austrian Breast & Colorectal Cancer Study Group
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Oct 5, 2023
Primary completion
Mar 4, 2030 (estimated)
Completion
May 6, 2037 (estimated)
Last update
Aug 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9833

Start the discussion